Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Regenxbio (RGNX) over the last 11 years, with Q3 2025 value amounting to $491000.0.

  • Regenxbio's Capital Expenditures rose 5061.35% to $491000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.0 million, marking a year-over-year increase of 2021.75%. This contributed to the annual value of $2.4 million for FY2024, which is 7554.22% down from last year.
  • Per Regenxbio's latest filing, its Capital Expenditures stood at $491000.0 for Q3 2025, which was up 5061.35% from $391000.0 recorded in Q2 2025.
  • In the past 5 years, Regenxbio's Capital Expenditures registered a high of $31.0 million during Q1 2021, and its lowest value of $326000.0 during Q3 2024.
  • Over the past 5 years, Regenxbio's median Capital Expenditures value was $2.6 million (recorded in 2023), while the average stood at $6.8 million.
  • In the last 5 years, Regenxbio's Capital Expenditures skyrocketed by 57000.0% in 2021 and then tumbled by 8843.92% in 2024.
  • Over the past 5 years, Regenxbio's Capital Expenditures (Quarter) stood at $14.6 million in 2021, then tumbled by 62.57% to $5.5 million in 2022, then plummeted by 79.41% to $1.1 million in 2023, then decreased by 4.17% to $1.1 million in 2024, then tumbled by 54.49% to $491000.0 in 2025.
  • Its Capital Expenditures stands at $491000.0 for Q3 2025, versus $391000.0 for Q2 2025 and $1.0 million for Q1 2025.